Study Summary
This trial is testing whether a new type of radiation therapy can help cancer patients by limiting side effects and improve disease control.
Eligible Conditions
- Lung Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 5 Secondary · Reporting Duration: Baseline to study end (up to 5 years)
6 weeks
Limited G3L Toxicity
Year 5
Change in Neutrophil to Lymphocyte ratio (NLR)
Local Recurrence (LR)
Metastasis Free Survival (MFS)
Overall Survival (OS)
Progression free Survival (PFS)
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Radiation Dose Limitations to VMAT
1 of 1
Experimental Treatment
55 Total Participants · 1 Treatment Group
Primary Treatment: Evidence-based radiation dose limitation to the vertebral bone marrow · No Placebo Group · N/A
Radiation Dose Limitations to VMAT
Other
Experimental Group · 1 Intervention: Evidence-based radiation dose limitation to the vertebral bone marrow · Intervention Types: OtherTrial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to study end (up to 5 years)
Who is running the clinical trial?
The University of Texas Health Science Center at San AntonioLead Sponsor
397 Previous Clinical Trials
73,612 Total Patients Enrolled
Neil Newman, MDPrincipal InvestigatorThe University of Texas Health Science Center - Mays Cancer Center
Eligibility Criteria
Age 18+ · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:You have a stage IV, M1 disease, in which definitive concurrent chemoradiotherapy to the thorax is planned.
AST/ALT ratio <2.5 times of ULN.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments